ProfileGDS5678 / 1449441_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 76% 77% 80% 84% 80% 78% 77% 79% 80% 78% 78% 78% 78% 78% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.1107976
GSM967853U87-EV human glioblastoma xenograft - Control 25.2493177
GSM967854U87-EV human glioblastoma xenograft - Control 35.7176880
GSM967855U87-EV human glioblastoma xenograft - Control 46.3773484
GSM967856U87-EV human glioblastoma xenograft - Control 55.7364780
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.2091278
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.1844377
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.4834979
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.6035980
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.4158178
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.4168378
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.40578
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.3343678
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.317878